Does Medicare Cover Wegovy? Insurance Guide 2026
Bold opening
In 2026, many Medicare beneficiaries are asking whether their insurance will cover Wegovy, the popular weight-loss and diabetes management medication. Wegovy, a brand name for semaglutide, has gained significant attention for its effectiveness in promoting weight loss and improving blood sugar control. However, navigating Medicare coverage for Wegovy can be complex, as policies vary depending on the condition being treated and the specific Medicare plan. This guide will break down everything you need to know about Medicare’s stance on Wegovy, including coverage for diabetes and weight loss, cost considerations, prior authorization requirements, and steps to take if your claim is denied.
Does Medicare Cover Wegovy for Diabetes?
Medicare does provide coverage for Wegovy when it is prescribed for the treatment of type 2 diabetes, but under a different name. Wegovy contains the same active ingredient—semaglutide—as Ozempic, which is FDA-approved for diabetes management. Since Medicare Part D covers prescription drugs, including those for diabetes, beneficiaries can access semaglutide through their Part D plan if their doctor prescribes it for blood sugar control.
However, there are caveats. Medicare will only cover Wegovy for diabetes if the prescription specifies its use for glycemic control, not weight loss. This distinction is critical because Wegovy is approved at a higher dose (2.4 mg) for chronic weight management, while Ozempic is approved for diabetes at lower doses (0.5 mg, 1 mg, or 2 mg). If a doctor prescribes Wegovy for diabetes, they may need to justify the higher dose or prescribe Ozempic instead to ensure coverage. Additionally, beneficiaries must meet their plan’s formulary requirements, which may include step therapy or prior authorization.
Does Medicare Cover Wegovy for Weight Loss?
Medicare does not cover Wegovy when it is prescribed solely for weight loss. This is due to a long-standing federal law, the Medicare Modernization Act of 2003, which explicitly excludes coverage for weight-loss medications under Medicare Part D. The law was designed to limit spending on drugs deemed “cosmetic” or non-essential, though critics argue it fails to account for the medical necessity of weight management in preventing obesity-related conditions like heart disease and diabetes.
Despite Wegovy’s FDA approval for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with weight-related comorbidities, Medicare beneficiaries are left without coverage for this indication. Some advocates are pushing for legislative changes, such as the Treat and Reduce Obesity Act, which would expand Medicare coverage to include obesity treatments like Wegovy. Until such reforms pass, however, beneficiaries must pay out-of-pocket for Wegovy if prescribed for weight loss or seek alternative treatments.
How Much Does Wegovy Cost With Medicare?
The cost of Wegovy with Medicare depends on whether it is prescribed for diabetes or weight loss. For diabetes management, Wegovy (or its lower-dose counterpart, Ozempic) is typically covered under Medicare Part D, but beneficiaries may still face significant out-of-pocket expenses. Without insurance, Wegovy retails for approximately $1,300 to $1,600 per month. With Medicare Part D coverage, the cost can drop to a copay ranging from $25 to $100 per month, depending on the plan’s formulary tier and the beneficiary’s coverage phase (e.g., deductible, initial coverage, or catastrophic coverage).
For weight loss, Medicare does not cover Wegovy, so beneficiaries must pay the full retail price. Some may qualify for manufacturer savings programs, such as Novo Nordisk’s patient assistance program, which offers discounts or free medication to eligible individuals with low incomes. Additionally, coupons or pharmacy discount cards (e.g., GoodRx) can reduce the cost by up to 50%, though these savings are not applicable to Medicare beneficiaries due to federal regulations. It’s essential to compare Part D plans annually during open enrollment to find the most cost-effective option for Wegovy coverage.
Wegovy Prior Authorization for Medicare
Prior authorization is a common requirement for Wegovy under Medicare Part D plans, particularly when prescribed for diabetes. This process requires a doctor to submit documentation proving the medical necessity of Wegovy before Medicare will approve coverage. For diabetes, prior authorization may involve demonstrating that the patient has tried and failed to achieve glycemic control with other medications, such as metformin or sulfonylureas. The doctor may also need to provide lab results, such as HbA1c levels, to justify the prescription.
For weight loss, prior authorization is irrelevant since Medicare does not cover Wegovy for this purpose. However, if a beneficiary is prescribed Wegovy for diabetes but also has obesity, the doctor should emphasize the diabetes diagnosis in the prior authorization request to avoid denial. Medicare Advantage plans (Part C) may have additional prior authorization requirements, so beneficiaries should check with their plan administrator. If prior authorization is denied, patients can appeal the decision through their Part D plan’s formal appeals process.
How to Get Medicare to Cover Wegovy
To maximize the chances of Medicare covering Wegovy, beneficiaries should follow several key steps. First, ensure the prescription is written for an FDA-approved indication—diabetes management—rather than weight loss. The doctor should specify the lower dose (e.g., 0.5 mg or 1 mg) associated with Ozempic to align with Medicare’s coverage policies. If a higher dose is medically necessary, the doctor must provide detailed clinical notes justifying the need.
Second, verify that Wegovy is included in the beneficiary’s Part D plan formulary. Medicare’s Plan Finder tool can help compare formularies and identify plans that cover semaglutide. Third, work with the doctor to complete any required prior authorization forms, including evidence of failed alternative treatments. Finally, if the prescription is denied, beneficiaries can file an appeal with their Part D plan, providing additional documentation from their doctor to support the claim. Persistence and thorough documentation are critical to securing coverage.
What to Do If Medicare Denies Wegovy
If Medicare denies coverage for Wegovy, beneficiaries have the right to appeal the decision through a multi-level process. The first step is to request a “redetermination” from the Part D plan, which involves submitting a written appeal within 60 days of the denial. The appeal should include a letter from the doctor explaining why Wegovy is medically necessary, along with supporting clinical evidence, such as lab results or records of failed alternative treatments.
If the redetermination is denied, the next step is to request a review by an Independent Review Entity (IRE) contracted by Medicare. This process can take up to 30 days. If the IRE upholds the denial, beneficiaries can escalate the appeal to an Administrative Law Judge (ALJ) hearing, which is typically reserved for cases involving high-cost medications. Throughout the appeals process, beneficiaries should keep detailed records of all communications and submissions. Legal assistance from a Medicare advocate or attorney may also improve the chances of a successful appeal.
Medicare Alternatives If Wegovy Is Not Covered
If Medicare denies coverage for Wegovy, beneficiaries have several alternatives to explore. For diabetes management, other GLP-1 receptor agonists like Ozempic, Trulicity (dulaglutide), or Victoza (liraglutide) may be covered under Part D. These medications work similarly to Wegovy but may have different dosing or administration requirements. Metformin, sulfonylureas, or SGLT2 inhibitors (e.g., Jardiance) are also widely covered and may be effective for glycemic control.
For weight loss, Medicare covers non-pharmacological treatments such as nutritional counseling (under Part B) and bariatric surgery for eligible beneficiaries. Intensive behavioral therapy (IBT) for obesity, provided by a primary care physician or specialist, is another covered option. Outside of Medicare, beneficiaries can explore weight-loss programs like Weight Watchers or Noom, though these are not covered by insurance. Some may also consider clinical trials for new obesity treatments, which often provide medications like Wegovy at no cost.
Frequently Asked Questions
Does Medicare cover Wegovy for weight loss?
No, Medicare does not cover Wegovy for weight loss due to federal laws excluding coverage for weight-loss medications. Wegovy is only covered when prescribed for type 2 diabetes management under a different name (e.g., Ozempic). Advocacy efforts are underway to expand Medicare coverage for obesity treatments, but no changes have been implemented as of 2026.
How much is the Wegovy copay with Medicare?
The copay for Wegovy with Medicare varies by Part D plan but typically ranges from $25 to $100 per month for diabetes management. The exact cost depends on the plan’s formulary tier, the beneficiary’s coverage phase, and whether the prescription is for Wegovy or its lower-dose counterpart, Ozempic. For weight loss, Medicare does not cover Wegovy, so beneficiaries must pay the full retail price.
Can I appeal if Medicare denies Wegovy?
Yes, beneficiaries can appeal a Medicare denial for Wegovy through a multi-level process, starting with a redetermination request to the Part D plan. If denied, the next steps include an Independent Review Entity (IRE) review and an Administrative Law Judge (ALJ) hearing. Success often depends on providing strong clinical evidence from the doctor justifying the medical necessity of Wegovy. Legal assistance may improve the chances of approval.